CNTX — Context Therapeutics Share News
0.000.00%
Last trade - 00:00HealthcareMicro Cap
U.S. STOCKS ON THE MOVE-Fat Brands, Spotify, Uber Tech
U.S. STOCKS ON THE MOVE-Apple, PayPal, Pinterest
Brief: Context Therapeutics Reports Data From Mid-stage Study Of Uterus Cancer Drug
U.S. STOCKS ON THE MOVE-RedHill Biopharma, Tyson Foods, Dell Technologies
Context Therapeutics up on uterus cancer drug trial data
U.S. STOCKS ON THE MOVE-Ionis, PulteGroup, Atlas Technical, Tesla
U.S. STOCKS ON THE MOVE-A O Smith, Pentair, health insurers
Brief: Context Therapeutics' Clinical Partner Stemline Therapeutics Receives FDA Approval Of Orserdu
Context Therapeutics rises as clinical partner bags FDA approval
Brief: Context Therapeutics Received Notice Of Delisting From Nasdaq
Brief: Context Therapeutics And Lonza Enter Manufacturing Agreement For Bispecific Antibody Targeting Claudin 6-Positive Cancers
Brief: Context Therapeutics Highlights 2023 Corporate Priorities And Pipeline Milestones
U.S. RESEARCH ROUNDUP- Broadcom, Cooper Companies, Interdigital
Brief: Context Therapeutics Reports Preliminary Phase 2 Data For ONA-XR In Metastatic Breast Cancer
Brief: Context Therapeutics Files For Mixed Shelf Of Up To $100 Mln - SEC Filing
Brief: Context Therapeutics Reports Third Quarter 2022 Operating And Financial Results
Brief: Context Therapeutics® Amends Cash Guidance, Extends Runway Into Q1 2024
Brief: Context Therapeutics® Reports Second Quarter 2022 Operating And Financial Results
Brief: Context Therapeutics And Menarini Group Announce Clinical Trial Collaboration And Supply Agreement To Evaluate Ona-Xr And Elacestrant Combination